BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2018;15:854-63. [PMID: 29779392 DOI: 10.1513/AnnalsATS.201801-067OC] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Ibrahim A, Ibrahim A, Parimon T. Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases. Diagnostics (Basel) 2021;11:87. [PMID: 33430301 DOI: 10.3390/diagnostics11010087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ryerson CJ. Making Sense of Bronchoalveolar Lavage Lymphocytosis in Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc 2020;17:1382-3. [PMID: 33124908 DOI: 10.1513/AnnalsATS.202007-818ED] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, Vij R, Strek ME, Chung JH. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc 2019;16:580-8. [PMID: 30653927 DOI: 10.1513/AnnalsATS.201807-443OC] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 17.5] [Reference Citation Analysis]
4 Raghu G, Lederer DJ, Rabe KF. Cryobiopsy for Interstitial Lung Disease: The Heat Is On. Am J Respir Crit Care Med 2019;199:1183-4. [PMID: 30917297 DOI: 10.1164/rccm.201903-0682ED] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
5 Kwon BS, Choe J, Chae EJ, Hwang HS, Kim YG, Song JW. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res 2021;22:282. [PMID: 34719401 DOI: 10.1186/s12931-021-01879-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, Kitamura H, Enomoto N, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Hashisako M, Tanaka T, Terasaki Y, Kunugi S, Kitani M, Okuda R, Horiike Y, Enomoto Y, Yasui H, Hozumi H, Suzuki Y, Nakamura Y, Fukuoka J, Johkoh T, Kondoh Y, Ogura T, Inoue Y, Hasegawa Y, Inase N, Homma S, Suda T. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J 2019;53:1802243. [PMID: 30880283 DOI: 10.1183/13993003.02243-2018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
7 Kreuter M, Maher TM, Corte TJ, Molina-Molina M, Axmann J, Gilberg F, Kirchgaessler KU, Cottin V. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Adv Ther 2022;39:1081-95. [PMID: 34936057 DOI: 10.1007/s12325-021-02009-w] [Reference Citation Analysis]
8 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir 2022:S0761-8425(22)00026-2. [PMID: 35304014 DOI: 10.1016/j.rmr.2022.01.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Salonen J, Purokivi M, Bloigu R, Kaarteenaho R. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res 2020;7:e000563. [PMID: 32265195 DOI: 10.1136/bmjresp-2020-000563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Marinescu DC, Ryerson CJ. Endobronchial Optical Coherence Tomography for the Diagnosis of Fibrotic Interstitial Lung Disease: A Light at the End of the Tunnel? Am J Respir Crit Care Med 2021;204:1122-4. [PMID: 34473937 DOI: 10.1164/rccm.202108-1899ED] [Reference Citation Analysis]
11 Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019;20:57. [PMID: 30871560 DOI: 10.1186/s12931-019-1022-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 20.3] [Reference Citation Analysis]
12 Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res 2020;21:32. [PMID: 31996266 DOI: 10.1186/s12931-020-1296-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 13.5] [Reference Citation Analysis]
13 Krauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch RC, Tello S, Korfei M, Mahavadi P, Breithecker A, Fink L, Stoehr M, Majeed RW, Seeger W, Crestani B, Guenther A. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). J Clin Med 2020;9:E2499. [PMID: 32756496 DOI: 10.3390/jcm9082499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Harari S, Cereda F, Pane F, Cavazza A, Papanikolaou N, Pelosi G, Scarioni M, Uslenghi E, Zompatori M, Caminati A. Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure. Medicina (Kaunas) 2019;55:E606. [PMID: 31546869 DOI: 10.3390/medicina55090606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Enomoto N, Naoi H, Aono Y, Katsumata M, Horiike Y, Yasui H, Karayama M, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2020;14:1753466620935774. [PMID: 32600180 DOI: 10.1177/1753466620935774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Maher TM, Wuyts W. Management of Fibrosing Interstitial Lung Diseases. Adv Ther 2019;36:1518-31. [PMID: 31119691 DOI: 10.1007/s12325-019-00992-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
17 Molina-molina M, Kreuter M, Cottin V, Corte TJ, Gilberg F, Kirchgaessler K, Axmann J, Maher TM. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Front Med 2022;9:897102. [DOI: 10.3389/fmed.2022.897102] [Reference Citation Analysis]
18 Jafri S, Ahmed N, Saifullah N, Musheer M. Epidemiology and Clinico-radiological features of Interstitial Lung Diseases. Pak J Med Sci 2020;36:365-70. [PMID: 32292435 DOI: 10.12669/pjms.36.3.1046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Sarkar P, Avram C, Chaudhuri N. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Rev Respir Med 2020;14:1001-8. [PMID: 32567402 DOI: 10.1080/17476348.2020.1784730] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Olson AL, Patnaik P, Hartmann N, Bohn RL, Garry EM, Wallace L. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis. Adv Ther 2021;38:4100-14. [PMID: 34156606 DOI: 10.1007/s12325-021-01786-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
21 Chen X, Guo J, Yu D, Jie B, Zhou Y. Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases. Front Pharmacol 2021;12:754851. [PMID: 34712141 DOI: 10.3389/fphar.2021.754851] [Reference Citation Analysis]
22 Adegunsoye A, Oldham JM, Bonham C, Hrusch C, Nolan P, Klejch W, Bellam S, Mehta U, Thakrar K, Pugashetti JV, Husain AN, Montner SM, Straus CM, Vij R, Sperling AI, Noth I, Strek ME, Chung JH. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. Am J Respir Crit Care Med 2019;199:747-59. [PMID: 30216085 DOI: 10.1164/rccm.201804-0761OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
23 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022:S0761-8425(22)00035-3. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Reference Citation Analysis]
24 Fujisawa T, Horiike Y, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Kataoka K, Hashisako M, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T. Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias. Respir Res 2021;22:290. [PMID: 34758816 DOI: 10.1186/s12931-021-01892-9] [Reference Citation Analysis]
25 Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020;55:2000085. [PMID: 32217654 DOI: 10.1183/13993003.00085-2020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
26 Goos T, De Sadeleer LJ, Yserbyt J, Verleden GM, Vermant M, Verleden SE, Wuyts WA. Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. J Clin Med 2021;10:1330. [PMID: 33807034 DOI: 10.3390/jcm10061330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ryerson CJ. POINT: Should Surgical Lung Biopsy Still Be Performed for Interstitial Lung Disease Evaluation? Yes. Chest 2021;160:2007-11. [PMID: 34872665 DOI: 10.1016/j.chest.2021.06.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Calyeca J, Balderas-Martínez YI, Olmos R, Jasso R, Maldonado V, Rivera Q, Selman M, Pardo A. Accelerated aging induced by deficiency of Zmpste24 protects old mice to develop bleomycin-induced pulmonary fibrosis. Aging (Albany NY) 2018;10:3881-96. [PMID: 30530916 DOI: 10.18632/aging.101679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tolle LB. Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease. Case Rep Pulmonol 2022;2022:9942432. [PMID: 35211349 DOI: 10.1155/2022/9942432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]